OpenBilldrug price receipt

NADAC week of 2026-10-14

XOFLUZA 40 MG TABLET

FDA nonproprietary name: baloxavir marboxil

For 30 tablets

Pharmacies pay

$4,858.16 filed

30 × $161.93879 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$4,767.56 filed

30 × $158.91877 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

0.98× estimated

Medicare paid about what pharmacies pay.

Part D averages every strength and form sold under “Xofluza” / “Baloxavir Marboxil” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$5,591.88 estimated

$4,858.16 + $728.72 (15%) + $5.00 fee per fill = $5,591.88

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

XOFLUZA 40 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as baloxavir marboxil, under the trade name “Xofluza”.

FDA gives its dosage form as tablet, film coated and its route as oral.

The labeler, the company named on the label, is Genentech, Inc.

FDA’s Established Pharmacologic Class for it is Polymerase Acidic Endonuclease Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 50242-0860-01.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $4,858.16 for 30 tablets (30 × $161.93879 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

The NDC

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name baloxavir marboxil with XOFLUZA 40 MG TABLET.

ProductPharmacies pay per unitMedicare per unit
XOFLUZA 40 MG TABLET this page
brand · tablet, film coated
$161.93879 per EA filed
eff. 2026-09-23
$158.91877 per EA filed
Part D 2024 average
XOFLUZA 80 MG TABLET
brand · tablet, film coated
$161.9469 per EA filed
eff. 2026-09-23
$158.91877 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

What Medicare paid

Medicare Part D paid $4,767.56 for 30 tablets, at an average of $158.91877 per EA in 2024 (2024-01-01 to 2024-12-31) for “Xofluza” and “Baloxavir Marboxil”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 7,723 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for XOFLUZA 40 MG TABLET labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Xofluza / Baloxavir Marboxil: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.